We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$6.95M
Cap. Flow
-$1.04M
Cap. Flow %
-0.83%
Top 10 Hldgs %
37.72%
Holding
74
New
9
Increased
25
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.42M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.55M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$1.03M
4
PCRX icon
Pacira BioSciences
PCRX
+$949K
5
ARRY
Array Biopharma Inc
ARRY
+$886K

Top Sells

Rank Stock Value
1
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.15M
2
PCYC
PHARMACYCLICS INC
PCYC
+$3.48M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.73M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$912K
5
TENX icon
Tenax Therapeutics
TENX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 82.86%
2 Miscellaneous 16.89%
3 Financials 0.25%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
26
DELISTED
TESARO, Inc.
TSRO
$1.76M 1.4%
30,000
+10,000
+50% +$574K
EPZM
27
DELISTED
Epizyme, Inc
EPZM
$1.74M 1.38%
72,379
+24,040
+50% +$463K
XBI icon
28
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$1.35M 1.07%
+3,000
New +$233K
VCEL icon
29
Vericel Corp
VCEL
$2.11B
$1.29M 1.02%
362,157
– –
ASMB icon
30
Assembly Biosciences
ASMB
$709M
$1.25M 0.99%
5,417
– –
ESPR
31
DELISTED
Esperion Therapeutics
ESPR
$1.23M 0.97%
15,000
– –
AVDL
32
DELISTED
Avadel Pharmaceuticals
AVDL
$1.1M 0.87%
51,788
+10,000
+24% +$179K
UTHR icon
33
United Therapeutics
UTHR
$22.6B
$939K 0.74%
5,399
+186
+4% +$33.5K
NSTG
34
DELISTED
NanoString Technologies, Inc.
NSTG
$925K 0.73%
+60,000
New +$802K
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.59B
$922K 0.73%
9,000
-3,000
-25% -$233K
MACK
36
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$890K 0.7%
9,152
– –
CMRX
37
DELISTED
Chimerix, Inc.
CMRX
$885K 0.7%
19,152
– –
STML
38
DELISTED
Stemline Therapeutics, Inc.
STML
$883K 0.7%
75,000
– –
INFI
39
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$876K 0.69%
+80,000
New +$1.03M
AMGN icon
40
Amgen
AMGN
$236B
$852K 0.67%
5,550
+612
+12% +$98K
XNPT
41
DELISTED
XENOPORT, INC.
XNPT
$797K 0.63%
130,000
– –
CRIS icon
42
Curis
CRIS
$3.64M
$712K 0.56%
+108
New +$649K
OCRX
43
DELISTED
Ocera Therapeutics, Inc.
OCRX
$709K 0.56%
186,573
+3,900
+2% +$15K
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$670K 0.53%
+21,667
New +$728K
RLYP
45
DELISTED
RELYPSA INC COM
RLYP
$596K 0.47%
18,000
– –
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
$591K 0.47%
66,704
– –
ARWR icon
47
Arrowhead Research
ARWR
$12.5B
$587K 0.46%
82,133
– –
ZGNX
48
DELISTED
Zogenix, Inc.
ZGNX
$504K 0.4%
37,500
– –
GILD icon
49
Gilead Sciences
GILD
$185B
$496K 0.39%
4,234
+583
+16% +$63.7K
TLPH icon
50
Talphera
TLPH
$63.8M
$424K 0.34%
4,998
– –
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opus Point Partners Management held 74 positions worth $126M, up 5.8% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opus Point Partners Management's Q2 2015 filing shows 9 new, 25 increased, 7 reduced and 17 closed positions. Its largest new stake was AstraZeneca: 50,000 shares worth $3.19M. The largest sale was SALIX PHARMACEUTICALS LTD DEL, an estimated $4.15M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.

  • Opus Point Partners Management's largest Q2 2015 buy was AstraZeneca: 50,000 shares worth $3.19M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2015, an estimated $1.55M increase.
  • Opus Point Partners Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $307K.
  • Opus Point Partners Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $4.15M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $126M portfolio in Q2 2015.
  • Opus Point Partners Management opened 9 new positions and closed 17 in Q2 2015.
  • Opus Point Partners Management's portfolio value rose 5.8% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.